Search for Symbols, analysts, keywords Log in ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM Apr. 30, 2025 5:31 PM ET ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Topline results were announced from part 1 of a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

The bottom line For the millions of Americans living with fatty liver disease, particularly those with the more severe form known as MASH, semaglutide represents a promising new treatment option.

RICHMOND, Va., April 30, 2025 (GLOBE NEWSWIRE) -- An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and ...

Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

Alcohol can further inflame your liver, making MASH symptoms worse. Learn if and how you can drink with MASH and what medications may cause side effects.

Adverse events leading to trial discontinuation were 2.6% for the semaglutide group and 3.3% for the placebo group. 1 Semaglutide 2.4 mg is not approved in the US for the treatment of MASH.

Semaglutide is not approved to treat MASH in the U.S. Pharmaceutical maker Novo Nordisk has said it plans to seek regulatory approval for its use in treating liver disease sometime this year.